Mumps: A resurgent disease with protean manifestations

Medical Journal of Australia

Volumn 189, Issue 8, 2008, Pages 456-459

  Senanayake, Sanjaya N ^a  

^a CANBERRA HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; ANALGESIC AGENT; ANTIPYRETIC AGENT; IMMUNOGLOBULIN; IODINATED CONTRAST MEDIUM; MEASLES MUMPS RUBELLA VACCINE; MEASLES MUMPS VACCINE; MUMPS VACCINE; RADIOACTIVE IODINE; THIAZIDE DIURETIC AGENT;

ARTICLE; ASEPTIC MENINGITIS; ASTHENOSPERMIA; AUSTRALIA; CEREBROSPINAL FLUID EXAMINATION; CLINICAL FEATURE; DRUG EFFICACY; DRUG FEVER; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; INFECTION CONTROL; INFECTION RATE; INJECTION SITE REACTION; MENINGITIS; MENINGOENCEPHALITIS; MUMPS; NONHUMAN; OLIGOSPERMIA; ORCHITIS; OTALGIA; PANCREATITIS; PAROTID SWELLING; PAROTITIS; PERCEPTION DEAFNESS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCROTAL PAIN; SEROCONVERSION; SINGLE DRUG DOSE; SWELLING; TESTIS ATROPHY; VACCINATION REACTION; VACCINE FAILURE; VIRUS CULTURE; VIRUS TRANSMISSION;

EID: 56349172182     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2008.tb02121.x     Document Type: Article

References (40)

1. Mühlemann K. The molecular epidemiology of mumps virus. Infect Genet Evol 2004; 4: 215-219.
2. Brotherton J, Wang H, Schaffer A, et al. Vaccine preventable diseases and vaccine coverage in Australia, 2003 to 2005. Commun Dis Intell 2007; 31 Suppl: S1-S152.
3. Bonnet MC, Dutta A, Weinberger C, Plotkin SA. Mumps vaccine virus strains and aseptic meningitis. Vaccine 2006; 24: 7037-7045.
4. Mumps virus vaccines. Wkly Epidemiol Rec 2007; 82: 51-60.
5. Gemmill IM. Mumps vaccine: is it time to re-evaluate our approach? CMAJ 2006; 175: 491-492.
6. Centers for Disease Control and Prevention. Update: multistate outbreak of mumps - United States, January 1-May 2, 2006. MMWR Morb Mortal Wkly Rep 2006; 55: 559-563.
7. Cohen C, White JM, Savage EJ, et al. Vaccine effectiveness estimates, 2004-2005 mumps outbreak, England. Emerg Infect Dis 2007; 13: 12-17.
8. Gupta RK, Best J, MacMahon E. Mumps and the UK epidemic 2005. BMJ 2005; 330: 1132-1135.
9. Australian Department of Health and Ageing. National Notifiable Diseases Surveillance System. http://www9.health.gov.au/cda/Source/CDA-index.cfm (accessed Aug 2008).
10. Narita M, Matsuzono Y, Takekoshi Y, et al. Analysis of mumps vaccine failure by means of avidity testing for mumps virus-specific immunoglobulin G. Clin Diagn Lab Immunol 1998: 5: 799-803.
11. Nöjd J, Tecle T, Samuelsson A, Orvell C. Mumps virus neutralizing antibodies do not protect against reinfection with a heterologous mumps virus geno-type. Vaccine 2001; 19: 1727-1731.
12. Atrasheuskaya AV, Kulak MV, Rubin S, Ignatyev GM. Mumps vaccine failure investigation in Novosibirsk, Russia, 2002-2004. Clin Microbiol Infect 2007; 13: 670-676.
13. Singh R, Mostafid H, Hindley RG. Measles, mumps and rubella - the urologist's perspective. Int J Clin Pract 2006; 60: 335-339.
14. Litman N, Baum SG. Mumps virus. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious cliseases. 6th ed. Philadelphia: Churchill Livingstone, 2005: 2003-2008.
15. Campos-Outcalt D. Mumps epidemic in 2006: are you prepared to detect and prevent it? J Fam Pract 2006; 55: 500-502.
16. Gut JP, Lablache C, Behr S, Kirn A. Symptomatic mumps virus reinfections. J Med Virol 1995; 45: 17-23.
17. World Health Organization. WHO-recommended surveillance standard of mumps. http://www.who.int/immunization_monitoring/diseases/ mumps_surveillance/en/index.html (accessed Aug 2008).
18. Centers for Disease Control and Prevention. Mumps case definition and case classification (CSTE). http://www.cdc.gov/nip/diseases/mumps/ case-def.htm (accessed Aug 2008).
19. Hviid A, Rubin S, Mühlemann K. Mumps. Lancet 2008; 371: 932-944.
20. Kawashima Y, Ihara K, Nakamura M, et al. Epidemiological study of mumps deafness in Japan. Auris Nasus Larynx 2005; 32: 125-128.
21. Taparelli F, Squadrini F, De Rienzo B, et al. Isolation of mumps virus from vaginal secretions in association with oophoritis. J Infect 1988; 17: 255-258.
22. Caranasos GJ, Felker JR. Mumps arthritis. Arch Intern Med 1967; 119: 394-398.
23. Ornoy A, Tenenbaum A. Pregnancy outcome following infections by coxsackie, echo, measles, mumps, hepatitis, polio and encephalitis viruses. Reprod Toxicol 2006; 21:446-457.
24. Bajaj NP, Rose P, Clifford-Jones R, Hughes PJ. Acute transverse myelitis and Guillain-Barré overlap syndrome with serological evidence for mumps viraemia. Acta Neurol Scand 2001; 104: 239-242.
25. Mandel L, Surattanont F. Bilateral parotid swelling: a review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002; 93: 221-237.
26. Krause CH, Molyneaux PJ, Ho-Yen DO, et al. Comparison of mumps-IgM ELISAs in acute infection. J Clin Virol 2007; 38: 153-156.
27. Centers for Disease Control and Prevention. Mumps - laboratory testing for mumps infection Q & A. http://www.cdc.gov/vaccines/vpd-vac/mumps/ outbreak/faqs-lab-test-infect.htm (accessed Aug 2008).
28. Uchida K, Shinohara M, Shimada S, et al. Rapid and sensitive detection of mumps virus RNA directly from clinical samples by real-time PCR. J Med Virol 2005; 75: 470-474.
29. Forsberg P, Frydén A, Link H, Orvell C. Viral IgM and IgG antibody synthesis within the central nervous system in mumps meningitis. Acta Neurol Scand 1986; 73: 372-380.
30. Ukkonen P, Granström ML, Räsänen J, et al. Local production of mumps IgG and IgM antibodies in the cerebrospinal fluid of meningitis patients. J Med Virol 1981; 8: 257-265.
31. Poggio GP, Rodriguez C, Cisterna D, et al. Nested PCR for rapid detection of mumps virus in cerebrospinal fluid from patients with neurological diseases. J Clin Microbiol 2000; 38: 274-278.
32. Yeniyol CO, Sorguc S, Minareci S, Ayder AR. Role of interferon-alpha-2B in prevention of testicular atrophy with unilateral mumps orchitis. Urology 2000; 55: 931-933.
33. Erpenbach KH. Systemic treatment with interferon-alpha 2B: an effective method to prevent sterility after bilateral mumps orchitis. J Urol 1991; 146: 54-56.
34. Ku JH, Kim YH, Jeon YS, Lee NK. The preventive effect of systemic treatment with interferon-alpha2B for infertility from mumps orchitis. BJU Int 1999; 84: 839-842.
35. National Health and Medical Research Council. The Australian immunisation handbook. 8th ed. Canberra: NHMRC, 2003. http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/ Content/Handbook-home (accessed Aug 2008).
36. Davidkin I, Valle M, Julkunen I. Persistence of anti-mumps virus antibodies after a two-dose MMR vaccination. A nine-year follow-up. Vaccine 1995; 13: 1617-1622.
37. Harling R, White JM, Ramsay ME, et al. The effectiveness of the mumps component of the MMR vaccine: a case control study. Vaccine 2005; 23: 4070-4074.
38. Hinman AR, Irons B, Lewis M, Kandola K. Economic analyses of rubella and rubella vaccines: a global review. Bull World Health Organ 2002; 80: 264-270.
39. World Health Organization. Global Advisory Committee on Vaccine Safety. Adverse events following mumps vaccination [Internet]. Geneva: WHO, 2003. http://www.who.int/vaccine_safety/topics/mumps/statement/en (accessed Aug 2008).
40. Toovey S, Jamieson A. Pancreatitis complicating adult immunisation with a combined mumps measles rubella vaccine. A case report and literature review. Travel Med Infect Dis 2003; 1: 189-192.